Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00118209 is a phase 3 interventional trial sponsored by Alliance for Clinical Trials in Oncology. As of 21 Nov 2026, it is completed. It studies Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim and 4 more drugs in Large B Cell Lymphoma. The registry lists an enrollment of 524 participants at 47 sites in 1 country. The registry lists a start date of 31 May 2005 and a primary completion date of 31 Oct 2017. 2 of its registered investigators have a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00118209 |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional trial |
| Lead sponsor | Alliance for Clinical Trials in Oncology |
| Enrollment | 524 |
| Registered sites | 47 |
| Countries | 1 |
| Conditions | Large B Cell Lymphoma |
| Drugs | Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Prednisone, Rituximab and Vincristine |
| Start | 31 May 2005 |
| Primary completion | 31 Oct 2017 |
| Study completion | 15 Nov 2021 |
| Last update posted | 17 Nov 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rebecca and John Moores Ucsd Cancer Center
La Jolla
- Camino Medical Group - Treatment Center
Mountain View
- Palo Alto Medical Foundation
Palo Alto
- Naval Medical Center - San Diego
San Diego
- Saint Helena Hospital
St. Helena
- Eastern Connecticut Hematology and Oncology Associates
Norwich
- Ccop - Christiana Care Health Services
Newark
- Creticos Cancer Center at Advocate Illinois Masonic Medical Center
Chicago
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago
- University of Illinois Cancer Center
Chicago
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood
- Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
Baltimore
- Nih - Warren Grant Magnuson Clinical Center
Bethesda
- National Naval Medical Center
Bethesda
- Providence Cancer Institute at Providence Hospital - Southfield Campus
Southfield
- Christian Hospital Northeast-Northwest
St Louis
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
St Louis
- New Hampshire Oncology - Hematology, Pa at Payson Center for Cancer Care
Concord
- New Hampshire Oncology - Hematology, Pa - Hooksett
Hooksett
- Charles R. Wood Cancer Center at Glens Falls Hospital
Glens Falls
- New York Weill Cornell Cancer Center at Cornell University
New York
- James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester
- Presbyterian Cancer Center at Presbyterian Hospital
Charlotte
- Kinston Medical Specialists
Kinston
- Iredell Memorial Hospital
Statesville
- Wake Forest University Comprehensive Cancer Center
Winston-Salem
- Altru Cancer Center at Altru Hospital
Grand Forks
- Mercy Cancer Center at Mercy Medical Center
Canton
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
Columbus
- Geisinger Cancer Institute at Geisinger Health
Danville
- Easton Regional Cancer Center at Easton Hospital
Easton
- Geisinger Hazleton Cancer Center
Hazleton
- Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
Hershey
- Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
Pittsburgh
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
Wilkes-Barre
- Mountainview Medical
Berlin Corners
- Virginia Commonwealth University Massey Cancer Center
Richmond
- Madigan Army Medical Center - Tacoma
Tacoma
- Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Morgantown
- Marshfield Clinic - Marshfield Center
Marshfield
- Saint Joseph's Hospital
Marshfield
- Marshfield Clinic - Lakeland Center
Minocqua
- Ministry Medical Group at Saint Mary's Hospital
Rhinelander
- Marshfield Clinic - Indianhead Center
Rice Lake
- Marshfield Clinic at Saint Michael's Hospital
Stevens Point
- Saint Michael's Hospital Cancer Center
Stevens Point
- Marshfield Clinic - Weston Center
Weston
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00118209
Each answer restates registry values shown on this page.
What is NCT00118209?
NCT00118209 is a phase 3 interventional trial sponsored by Alliance for Clinical Trials in Oncology. It studies Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim and 4 more drugs in Large B Cell Lymphoma.
Who leads NCT00118209?
The registry names Andrew D. Zelenetz, MD, PhD (study chair, Memorial Sloan Kettering Cancer Center) and Wyndham H. Wilson, MD, PhD (study chair, National Cancer Institute (NCI)) as overall officials.
Where does NCT00118209 run?
The registry lists 47 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00118209 study?
The registered drug and biological interventions are Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Prednisone, Rituximab and Vincristine.
When did NCT00118209 end?
The registry lists a primary completion date of 31 Oct 2017 and a study completion date of 15 Nov 2021. The sponsor last updated the record on 17 Nov 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.